# Tissue-specific changes in expression of Vegfr2 in tumor and normal tissues of lymphoma-bearing BALB/c mice under chronic restraint stress

**Authors:** Alonso A. Orozco-Flores, Gloria Romero-Beltrán, Diana Caballero-Hernández, Deyanira Quistián-Martínez, Ricardo Gomez-Flores, Patricia Tamez-Guerra, Cristina Rodríguez-Padilla

PMC · DOI: 10.1186/s13104-025-07219-x · BMC Research Notes · 2025-04-14

## TL;DR

Chronic stress and tumor presence change Vegfr2 gene expression in different tissues of mice with lymphoma.

## Contribution

This study reveals how chronic stress and tumor burden interact to alter Vegfr2 expression in various tissues.

## Key findings

- Chronic stress and tumor burden alter Vegfr2 expression in multiple tissues.
- Vegfr2 expression in skeletal muscle is enhanced 23-fold when stress and tumor burden co-occur.
- Inguinal adipose tissue shows decreased Vegfr2 in tumor-free mice under stress, but increased in tumor-bearing mice.

## Abstract

Alteration of the expression of vascular endothelial growth factor (VEGF) and its receptors, VEGFR-1 and VEGFR-2, leads to aberrant angiogenesis in cancer; this is exacerbated by chronic stress. Our main aim was to determine the effect of chronic restraint stress on the expression of Vegfr2, the gene encoding VEGFR-2, in tumor, fat, skeletal muscle and brain in a murine model of lymphoma.

We found that both chronic stress and tumor burden alter Vegfr2 expression. Under chronic stress, Vegfr2 is differentially expressed in inguinal adipose tissue, decreasing in tumor-free, and increasing in tumor-bearing animals. In skeletal muscle, brain, and tumor, Vegfr2 expression was upregulated by chronic stress. Adipose tissue, brain and skeletal muscle of tumor-bearing animals also showed changes in Vegfr2 expression during tumor progression. We also found that for skeletal muscle the combination of chronic stress and tumor burden enhances Vegfr2 expression (23-folds).

Chronic stress and tumor burden influence Vegfr2 expression in normal and tumoral tissues and their co-occurrence enhances its effect on skeletal muscle.

## Linked entities

- **Genes:** KDR (kinase insert domain receptor) [NCBI Gene 3791]
- **Proteins:** VEGFA (vascular endothelial growth factor A), FLT1 (fms related receptor tyrosine kinase 1), KDR (kinase insert domain receptor)
- **Diseases:** lymphoma (MONDO:0003659)

## Full-text entities

- **Genes:** Flt1 (FMS-like tyrosine kinase 1) [NCBI Gene 14254] {aka Flt-1, VEGFR-1, VEGFR1, sFlt1}, Kdr (kinase insert domain protein receptor) [NCBI Gene 16542] {aka 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}
- **Diseases:** cancer (MESH:D009369), lymphoma (MESH:D008223)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** /c — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_9103)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11998259/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11998259/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11998259/full.md

---
Source: https://tomesphere.com/paper/PMC11998259